ArriVent BioPharma, Inc Common Stock
Price & Volume
Stats
See more52W Range | $15.47-$29.71 |
Market Cap | $921.3M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$4.15 |
News
See moreYahoo Finance • 4 days ago
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
Yahoo Finance • 3 months ago
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
Yahoo Finance • 4 months ago
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Yahoo Finance • 5 months ago
ArriVent expects topline data from lung cancer drug trial in early 2026
About
CEO | Dr. Zhengbin Yao Ph.D. |
CFO | Mr. Winston Kung M.B.A. |
Address | 18 Campus Boulevard, Newtown Square, PA, United States, 19073 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 52 |
